Call Us Now

+91 9606900005 / 04

For Enquiry

legacyiasacademy@gmail.com

MERIL’S DEVICE

Why in news?

Three years after setting cap on stents, NPPA exempts Meril’s device from price control

Details

  • Meril had approached the NPPA for exemption under this provision after it received the Indian drug regulator’s approval in 2017 for the stent, a drug-coated product called MeRes-100 that naturally dissolves over a period of time.
  • The All India Drug Action Network (AIDAN) last year had raised concerns related to the safety of the product.
  • The authority took the decision after DCGI, which convened a meeting of experts on the issue, had found clinical data and three-year follow up data on 108 patients submitted by Meril to be “satisfactory”



Download PDF
December 2022
MTWTFSS
 1234
567891011
12131415161718
19202122232425
262728293031 
Categories